奎的平治疗晚发精神分裂症的临床观察

Clinical observe of quetiapine in the treatment of late-onset schizophrenia

目的:对比奎的平和氯丙嗪治疗晚发精神分裂症的疗效与安全性.方法:分别采用国产的奎的平与氯丙嗪随机治疗96例晚发精神分裂症,奎的平组48例,200～400 mg-1氯丙嗪组48例,200～400 mg-1,连续观察8周,以PANSS、CGI和TESS量表评定症状、疗效和不良反应.结果:奎的平与氯丙嗪对晚发精神分裂症有确切疗效,奎的平有效率75.00%,氯丙嗪有效率72.92%,两组无显著性差异,奎的平组比氯丙嗪组有较少的不良反应.结论:奎的平是一种治疗晚发精神分裂症疗效好、安全、不良反应少、病人服用依从性好的药物.

Objective: To compare the efficacy and safety of homebred quetiapine and largactil for late-onset schizophrenia. Methods: 96 lste-onset schizophrenic patients were randomly treated with quetiapine or largactil for 8 weeks,there were 48 patients in each group respectively.The doses were 200-400mg-1.The PANSS、CGI and TESS were used to evaluate symptoms、efficacy and adverse effects respectively. Results: There are obviously efficacy of quetiapine and largactil for late-onset schizophrenia. The efficacy rate of quetiapine group and largactil group is 75.00% and 72.92% respectively,without any significant difference between two groups.The adverse effects of quetiapine group is less than that of largactil group.Conclusions: Quetiapine is a drug with good efficacy、safety、less adverse effect and good compliance in the treatment of late-onset schizophrenia.